Cargando…
Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells
Osteosarcoma (OS) is the most common primary malignancy of bone. Mortality is determined by the presence of metastatic disease, but little is known regarding the biochemical events that drive metastases. Two murine OS cell lines, K7M2 and K12, are related but differ significantly in their metastatic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586506/ https://www.ncbi.nlm.nih.gov/pubmed/23476113 http://dx.doi.org/10.1155/2013/480713 |
_version_ | 1782261314277605376 |
---|---|
author | Mu, Xiaodong Isaac, Christian Schott, Trevor Huard, Johnny Weiss, Kurt |
author_facet | Mu, Xiaodong Isaac, Christian Schott, Trevor Huard, Johnny Weiss, Kurt |
author_sort | Mu, Xiaodong |
collection | PubMed |
description | Osteosarcoma (OS) is the most common primary malignancy of bone. Mortality is determined by the presence of metastatic disease, but little is known regarding the biochemical events that drive metastases. Two murine OS cell lines, K7M2 and K12, are related but differ significantly in their metastatic potentials: K7M2 is highly metastatic whereas K12 displays much less metastatic potential. Using this experimental system, the mammalian target of rapamycin (mTOR) pathway has been implicated in OS metastasis. We also discovered that aldehyde dehydrogenase (ALDH, a stem cell marker) activity is higher in K7M2 cells than K12 cells. Rapamycin treatment reduces the expression and enzymatic activity of ALDH in K7M2 cells. ALDH inhibition renders these cells more susceptible to apoptotic death when exposed to oxidative stress. Furthermore, rapamycin treatment reduces bone morphogenetic protein-2 (BMP2) and vascular endothelial growth factor (VEGF) gene expression and inhibits K7M2 proliferation, migration, and invasion in vitro. Inhibition of ALDH with disulfiram correlated with decreased mTOR expression and activity. In conclusion, we provide evidence for interaction between mTOR activity, ALDH activity, and metastatic potential in murine OS cells. Our work suggests that mTOR and ALDH are therapeutic targets for the treatment and prevention of OS metastasis. |
format | Online Article Text |
id | pubmed-3586506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35865062013-03-09 Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells Mu, Xiaodong Isaac, Christian Schott, Trevor Huard, Johnny Weiss, Kurt Sarcoma Research Article Osteosarcoma (OS) is the most common primary malignancy of bone. Mortality is determined by the presence of metastatic disease, but little is known regarding the biochemical events that drive metastases. Two murine OS cell lines, K7M2 and K12, are related but differ significantly in their metastatic potentials: K7M2 is highly metastatic whereas K12 displays much less metastatic potential. Using this experimental system, the mammalian target of rapamycin (mTOR) pathway has been implicated in OS metastasis. We also discovered that aldehyde dehydrogenase (ALDH, a stem cell marker) activity is higher in K7M2 cells than K12 cells. Rapamycin treatment reduces the expression and enzymatic activity of ALDH in K7M2 cells. ALDH inhibition renders these cells more susceptible to apoptotic death when exposed to oxidative stress. Furthermore, rapamycin treatment reduces bone morphogenetic protein-2 (BMP2) and vascular endothelial growth factor (VEGF) gene expression and inhibits K7M2 proliferation, migration, and invasion in vitro. Inhibition of ALDH with disulfiram correlated with decreased mTOR expression and activity. In conclusion, we provide evidence for interaction between mTOR activity, ALDH activity, and metastatic potential in murine OS cells. Our work suggests that mTOR and ALDH are therapeutic targets for the treatment and prevention of OS metastasis. Hindawi Publishing Corporation 2013 2013-02-14 /pmc/articles/PMC3586506/ /pubmed/23476113 http://dx.doi.org/10.1155/2013/480713 Text en Copyright © 2013 Xiaodong Mu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mu, Xiaodong Isaac, Christian Schott, Trevor Huard, Johnny Weiss, Kurt Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells |
title | Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells |
title_full | Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells |
title_fullStr | Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells |
title_full_unstemmed | Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells |
title_short | Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells |
title_sort | rapamycin inhibits aldh activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586506/ https://www.ncbi.nlm.nih.gov/pubmed/23476113 http://dx.doi.org/10.1155/2013/480713 |
work_keys_str_mv | AT muxiaodong rapamycininhibitsaldhactivityresistancetooxidativestressandmetastaticpotentialinmurineosteosarcomacells AT isaacchristian rapamycininhibitsaldhactivityresistancetooxidativestressandmetastaticpotentialinmurineosteosarcomacells AT schotttrevor rapamycininhibitsaldhactivityresistancetooxidativestressandmetastaticpotentialinmurineosteosarcomacells AT huardjohnny rapamycininhibitsaldhactivityresistancetooxidativestressandmetastaticpotentialinmurineosteosarcomacells AT weisskurt rapamycininhibitsaldhactivityresistancetooxidativestressandmetastaticpotentialinmurineosteosarcomacells |